Agfa-Gevaert Co-opts MRP Consulting BV, Represented by Mark Pensaert, to Maintain its Board at Six Members Minimum
Agfa-Gevaert confirmed on Wednesday the resignation of Michel Govaert from the board of directors and co-opted Mark Pensaert to ensure continuity. This appointment follows the board's confirmation of Michel Govaert's resignation taking effect.
On Wednesday, the board of directors of Agfa-Gevaert co-opted MRP Consulting BV, represented by Mark Pensaert, as an independent director. This appointment aims to maintain the minimum number of six directors required by law. Pensaert, who previously served on the board from May 2018 to May 2026, returns temporarily to ensure continuity and allow the board to conduct its selection process to identify a successor to Michel Govaert.
Interim Period Activities
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
During this interim period, Mark Pensaert will also continue to serve as the chairman of the audit committee. The board expressed its gratitude towards Pensaert for his willingness to return temporarily.
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 512 millions d'euros
Quarterly revenue: 512 millions d'euros
Revenue growth: -2,2 %
EBITDA: 25 millions d'euros
EBITDA margin: 4,9 %
Net income: -27 millions d'euros
Free cash flow: -52 millions d'euros
127 millions d'euros
Guidance from the release
The full year 2026 free cash flow is expected to be more negative than in 2025
Risks mentioned
Flux de trésorerie disponible négatif de 52 M€ au S1 2026, aggravé par les coûts de transformation et de réorganisation
Faiblesse persistante du marché Green Hydrogen Solutions liée aux retards de mise en œuvre de la directive RED III
Baisse du chiffre d'affaires de HealthCare IT de 7,3% hors effet de change liée à la transition cloud
Opportunities identified
EBITDA ajusté du groupe en hausse de 66% au S1 2026 grâce aux programmes d'économies
Recettes récurrentes de HealthCare IT en hausse de 4% hors effet de change au T2 2026, où elles représentent 66% du chiffre d'affaires du segment
Amélioration du fonds de roulement dans toutes les activités hors film grâce à un programme d'affacturage avec BNP Paribas Fortis
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
